Gilead’s tie up with generic cos may not address HIV challenge

Gilead’s partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries with rising HIV rates are excluded, and the control over the active pharmaceutical ingredient could delay price reductions. Patient groups are challenging Gilead’s patents globally, fearing the VL aims to maintain the company’s monopoly.